Business
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, sugg
About this update from Abivax Sa
[{"type":"image","alt":"Abivax","displaySize":"","headline":null,"caption":"Abivax","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v57CPS2C3Q2FJGKeA0P43g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44}},"lazy":false},{"type":"text","content":"Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026","length":166,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Symptomatic response of obefazimod was observed as early as week 1 (first time point evaluated) with symptomatic remission observed at week 2 (nominally significant p-value <0.05) in a pooled analysis of ABTECT-1 and ABTECT-2","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Biomarker data from ABTECT-1 and ABTECT-2 induction trials indicate upregulation of miR-124 and reduction of key inflammatory cytokines (IL-17A and IL-6) toward homeostatic levels","length":179,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1022,"olType":false},{"type":"text","content":"PARIS, France – February 21, 2026 – 12:00 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing ...